title: Loss of response to epidermal growth factor and retinoic acid accompanies the transformation of human prostatic epithelial cells to tumorigenicity with v-Ki-ras.
abstract: Growth factor-independent proliferation and loss of response to differentiation factors are believed to be critical elements in carcinogenesis. We have developed an in vitro model of human prostatic carcinogenesis by the introduction of SV40 DNA into normal prostatic epithelial cells to create a transformed, immortal cell line, pRNS-1-1. This non-tumorigenic cell line responded similarly to normal prostatic epithelial cells to most growth- and differentiation-regulatory factors, with the notable exception of loss of response to the inhibitory factor 1,25-dihydroxyvitamin D3. In this study, we describe the introduction of the ras oncogene into pRNS-1-1 cells to create a tumorigenic cell line, pRNS-1-1/ras. In addition to an attenuated response to 1,25-dihydroxyvitamin D3, these cells also became unresponsive to retinoic acid and gained the ability to undergo clonal proliferation in the absence of epidermal growth factor (EGF). EGF-independent growth could not be linked to the production of autocrine transforming growth factor-alpha, but instead was likely due to sustained signaling by the ras oncogene, bypassing ligand-activation of the EGF receptor. Ligand-independent proliferation, coupled with the loss of response to the growth-inhibitory and differentiation agent retinoic acid, may be important elements in the conversion of human prostatic epithelial cells to tumorigenicity.
authors.affiliation: Department of Urology, Stanford University School of Medicine, CA 94305-5118, USA.
authors.forename: D M
authors.initials: DM
authors.lastname: Peehl
authors.forename: S T
authors.initials: ST
authors.lastname: Wong
authors.forename: R G
authors.initials: RG
authors.lastname: Sellers
authors.forename: S
authors.initials: S
authors.lastname: Jin
authors.forename: J S
authors.initials: JS
authors.lastname: Rhim
mesh_terms: D000818:Animals; D002117:Calcitriol / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects; D002471:Cell Transformation, Neoplastic; D002478:Cells, Cultured; D004815:Epidermal Growth Factor / Q000494:pharmacology*; D004848:Epithelium / Q000187:drug effects; D016220:Fibroblast Growth Factor 1 / Q000494:pharmacology; D011905:Genes, ras / Q000502:physiology*; D006801:Humans; D007633:Keratins / Q000378:metabolism; D008297:Male; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D011467:Prostate / Q000187:drug effects*; D013002:Somatomedins / Q000494:pharmacology; D016211:Transforming Growth Factor alpha / Q000032:analysis / Q000276:immunology; D014212:Tretinoin / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
chemical_list: D013002:Somatomedins; D016211:Transforming Growth Factor alpha; D014409:Tumor Necrosis Factor-alpha; D016220:Fibroblast Growth Factor 1; D014212:Tretinoin; D004815:Epidermal Growth Factor; D007633:Keratins; D002117:Calcitriol